 |
|
OHSU finds association between Epstein-Barr virus, inflammatory diseases of the mouth
November 11, 2008A new study, published in the Journal of Endodontics, finds a link between Epstein-Barr virus and the microorganisms that cause irreversible pulpitis and apical periodontitis
PORTLAND, Ore. - Researchers at Oregon Health & Science University's School of Dentistry (www.ohsu.edu/sod) have found that a significant percentage of dental patients with the inflammatory diseases irreversible pulpitis and apical periodontitis also have the Epstein-Barr virus. The Epstein-Barr virus is an important human pathogen found in more than 90 percent of the world population. It is associated with many diseases, including infectious mononucleosis, malignant lymphomas, and naspharyngeal carcinoma.
The findings are published online (www.jendodon.com/article/S0099-2399(08)00879-0/abstract) in the Journal of Endodontics, one of the leading peer-reviewed endodontology journals. The study also is expected to be published in the December 2008 (volume 34, issue 12) issue of the Journal of Endodontics.
Although the number of studies examining the role of herpesviruses in oral disease has been increasing, the majority of studies have focused on periodontitis, with no systematic attempt to examine herpesvirus in endodontic patients with varying inflammatory diseases. The OHSU study assessed the presence of human cytomegalovirus (HCMV), Epstein-Barr virus (EPV), herpes simplex virus (HSV-1), and Varicella zoster virus (VZV) in 82 endodontic patients, including patients with irreversible pulpitis and apical periodontitis, and compared them with 19 healthy patients. The goal of the study was to determine the potential association of herpesvirus with clinical symptoms, including acute pain and size of radiographic bone destruction.
Using a variety of methods, the OHSU team found the Epstein-Barr virus DNA and RNA in significantly higher percentages (43.9 percent and 25.6 percent respectively) compared with healthy patients (0 percent). Human cytomegalovirus DNA and RNA were found in measurable numbers in both endodontic patients (15.9 percent and 29.3 percent respectively) and in healthy patients (42.1 percent and 10.5 percent respectively). Herpes simplex virus DNA was found in low percentages of endodontic patients (13.4 percent) and only one patient showed the presence of Varicella zoster virus.
While a previous study examined the incidence of herpes viruses in apical periodontitis, "this is the first time irreversible pulpitis has been analyzed for the presence of herpes viruses and associated with Epstein-Barr virus," noted Curt Machida, Ph.D., OHSU professor of integrative biosciences and principal investigator, whose lab was host for the study. "The incidence of irreversible pulpitis and apical periodontitis, caused by bacteria and possibly the latent herpes virus, is painful and can greatly impair the body's natural immune system. Studies such as ours could someday lead to more effective treatments of inflammatory diseases of the mouth."
Oregon Health & Science University
Although the number of studies examining the role of herpesviruses in oral disease has been increasing, the majority of studies have focused on periodontitis, with no systematic attempt to examine herpesvirus in endodontic patients with varying inflammatory diseases. The OHSU study assessed the presence of human cytomegalovirus (HCMV), Epstein-Barr virus (EPV), herpes simplex virus (HSV-1), and Varicella zoster virus (VZV) in 82 endodontic patients, including patients with irreversible pulpitis and apical periodontitis, and compared them with 19 healthy patients. The goal of the study was to determine the potential association of herpesvirus with clinical symptoms, including acute pain and size of radiographic bone destruction.
Using a variety of methods, the OHSU team found the Epstein-Barr virus DNA and RNA in significantly higher percentages (43.9 percent and 25.6 percent respectively) compared with healthy patients (0 percent). Human cytomegalovirus DNA and RNA were found in measurable numbers in both endodontic patients (15.9 percent and 29.3 percent respectively) and in healthy patients (42.1 percent and 10.5 percent respectively). Herpes simplex virus DNA was found in low percentages of endodontic patients (13.4 percent) and only one patient showed the presence of Varicella zoster virus.
While a previous study examined the incidence of herpes viruses in apical periodontitis, "this is the first time irreversible pulpitis has been analyzed for the presence of herpes viruses and associated with Epstein-Barr virus," noted Curt Machida, Ph.D., OHSU professor of integrative biosciences and principal investigator, whose lab was host for the study. "The incidence of irreversible pulpitis and apical periodontitis, caused by bacteria and possibly the latent herpes virus, is painful and can greatly impair the body's natural immune system. Studies such as ours could someday lead to more effective treatments of inflammatory diseases of the mouth."
Oregon Health & Science University
Epstein-barr Virus Current Events and Epstein-barr Virus News RSSImmune therapy can protect against or treat later lymphoma
Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection.
Immunotherapy demonstrates long-term success in treating lymphoma
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).
Rare head and neck cancer linked to HPV, study finds
An increase in cases of a rare type of head and neck cancer appears to be linked to HPV, or human papillomavirus, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.
UCSF researchers identify new drug target for Kaposi's Sarcoma
UCSF researchers have identified a new potential drug target for the herpes virus that causes Kaposi's sarcoma, re-opening the possibility of using the class of drugs called protease inhibitors against the full herpes family of viruses, which for 20 years has been deemed too difficult to attain.
Epstein-Barr Virus May Be Associated with Progression of MS
Epstein-Barr virus (EBV), the pathogen that causes mononucleosis, appears to play a role in the neurodegeneration that occurs in persons with multiple sclerosis, researchers at the University at Buffalo and the University of Trieste, Italy, have shown.
Varicella zoster infection causes severe autoimmune hepatitis
Autoimmune hepatitis (AIH) is a chronic liver inflammation of unknown etiology that is characterized by the presence of circulatory autoantibodies and ongoing liver tissue damage.
A double-barreled immune cell approach for neuroblastoma
Adding an artificial tumor-specific receptor to immune system cells called T-lymphocytes that target a particular virus extended and improved the cells' ability to fight a form of childhood cancer called neuroblastoma, said researchers form Baylor College of Medicine and Texas Children's Hospital in a report that appears online today in the journal Nature Medicine.
NIH scientists discover crucial control in long-lasting immunity
National Institutes of Health (NIH) scientists have identified a protein that plays matchmaker between two key types of white blood cells, T and B cells, enabling them to interact in a way that is crucial to establishing long-lasting immunity after an infection.
U of T researchers reveal Epstein-Barr virus protein contributes to cancer
Researchers at the University of Toronto have discovered that the EBNA1 protein of Epstein-Barr virus (EBV) disrupts structures in the nucleus of nasopharyngeal carcinoma (NPC) cells, thereby interfering with cellular processes that normally prevent cancer development.
Vaccine shows promise in preventing mono
A new study suggests that a vaccine targeting Epstein-Barr virus (EBV) may prevent infectious mononucleosis, commonly known as "mono" or "glandular fever."
More Epstein-barr Virus Current Events and Epstein-barr Virus News Articles
 |
Epstein-Barr Virus (Infectious Disease and Therapy) by Alex Tselis (Editor), Hal B. Jenson (Editor) Filling a gap in the literature, this guide analyzes EBV infection and all of its associated disorders including infectious mononucleosis, Burkitt lymphoma, and Hodgkin's disease. Opening with a historical introduction, the reference progresses from molecular virology, epidemiology, immunology, and pathology to clinical presentation, diagnosis, disease detection, patient management, and vaccine development. |
 |
Epstein-Barr Virus Awareness Ribbon Mouse Pad by MyHeritageWear.com The Epstein-Barr Virus Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Epstein-Barr Virus Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Epstein-Barr Virus Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
From Fatigued to Fantastic by Jacob Teitelbaum (Author) The original, bestselling guide to treating chronic fatigue and fibromyalgia-now completely revised and updated. For the more than twenty-five million Americans who suffer from chronic fatigue, fibromyalgia, and other fatigue-related illnesses, there is only one bestselling guide-From Fatigued to Fantastic. This new, completely updated third edition incorporates the latest advances in science and technology to help alleviate the baffling, often dismissed symptoms associated with severe, almost unrelenting fatigue. Dr. Teitelbaum's integrated treatment program is based on the clinically proven results of his landmark study and on his more than thirty years of experience in working with patients to overcome their illnesses. Using the most current information, Dr. Teitelbaum... |
 |
Resist Immune System Tonic 750mg - 180 vegicaps., (Pacific Biologic) by HerbalLoveShop Resist is a very neutral tonic, meaning it can be used by a wide variety of individuals in different states of health. Many professionals supplement the diet with Resist when using programs designed to strengthen patients with reduced or compromised immune function. People with Chronic Fatigue Syndrome, Epstein-Barr virus, and those on chemotherapy or similarly damaging treatments, all are considered to have compromised immune function. Resist is mentioned in several books and journal articles written on various regimes, including diet, for the management of HIV; including published research by noted alternative HIV treatment specialist Jon Kaiser, MD. Resist is best used in conjunction with Resist 2 in daily rotation. |
|
Peak Immunity: How to Fight Epstein-Barr Virus, Candida, Herpes Simplex Viruses and Other Immuno-Depressive Conditions and Win by Luc De Schepper (Author) | |
 |
Epstein-Barr Virus by Erle S. Robertson (Editor) |
 |
Resist Immune System Tonic 750mg - 60 vegicaps., (Pacific Biologic) by HerbalLoveShop Resist is a very neutral tonic, meaning it can be used by a wide variety of individuals in different states of health. Many professionals supplement the diet with Resist when using programs designed to strengthen patients with reduced or compromised immune function. People with Chronic Fatigue Syndrome, Epstein-Barr virus, and those on chemotherapy or similarly damaging treatments, all are considered to have compromised immune function. Resist is mentioned in several books and journal articles written on various regimes, including diet, for the management of HIV; including published research by noted alternative HIV treatment specialist Jon Kaiser, MD. Resist is best used in conjunction with Resist 2 in daily rotation. |
|
Peak Immunity: How to Fight Epstein-Barr Virus, Candida, Herpes Simplex and other Immuno-Depressive Disorders and Win by M.D. Luc de Schepper (Author) | |
|
Waiting to Live: The Debilitating Effects of Chronic Epstein-Barr Virus by Gregg Charles Fisher (Author), MD Stephen E. Straus (Author), MD James M. Oleske (Author), Caren Heacock (Author), Bernard Fisher (Author) | |
|
Valacyclovir clears EBV in mono, may help prevent spread.(News)(Epstein-Barr virus): An article from: Family Practice News by Miriam E. Tucker (Author) This digital document is an article from Family Practice News, published by Thomson Gale on January 15, 2006. The length of the article is 498 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Valacyclovir clears EBV in mono, may help prevent spread.(News)(Epstein-Barr virus) Author: Miriam E. Tucker Publication: Family Practice News (Magazine/Journal) Date: January 15, 2006 Publisher: Thomson Gale Volume: 36 Issue: 2 Page: 5(1) Distributed by Thomson... |
| © 2009 BrightSurf.com |